News

The deal approved by the boards of directors from both companies will see Shire pay $46 per share in cash for NPS, which has expertise in gastrointestinal (GI)

As part of the deal, Precision’s NanoAssemblr platform will be used to manufacture GMP batches to support clinical trials and commercial development for RNA medicines developed using Arcturus’

Under the deal, discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a two-year period to meet predefined milestones, while Bayer will be

The acquisition is centered on development of the UK firm’s Phase II clinical candidate CNV1014802, which has showed clinical activity in proof of concept trials for trigeminal neuralgia

Both the trials, which met their primary efficacy endpoints, compared the reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks with alirocumab versus placebo in these

Currently, Syndax is developing entinostat, a Class I selective histone deacetylase (HDAC) inhibitor, in the US and Europe in combination with hormone therapy for advanced breast cancer and

Patent No. 8,916,588 "Methods of Treatment for Attention Deficit Hyperactivity Disorder" and Patent No. 8,927,010 "Compositions for Treatment of Attention Deficit Hyperactivity Disorder" are owned by Highland’s wholly

The vaccines work of Valera builds on a body of preclinical research at Moderna showing the ability of modified mRNA to express viral antigens in vivo and to

The clinical results reported are from 9 patients, 6 of which carried the worst KS prognosis. Also, 4 of the 9 patients had received from 1 to 8